CDC, ACIP approve Novavax Covid-19 vaccine under emergency use authorization
Share
Tweet
July 24, 2022
OKLAHOMA CITY – This week, the Centers for Disease Control and Prevention (CDC) endorsed the Advisory Committee on Immunization Practices’ (ACIP) recommendation of the Novavax Covid-19 vaccine for primary series vaccination in adults ages 18 and older.
Novavax is a two-dose, protein-based Covid-19 vaccine, adding another option to the Pfizer and Moderna mRNA vaccines and the Johnson & Johnson viral-vector vaccine.
“Protein subunit vaccines contain harmless pieces (proteins) of the Covid-19 virus alongside another ingredient, called an adjuvant, that helps the immune system respond to the virus...
For access to this article please
sign in or
subscribe.
Reader Comments(0)